FREETOWN --Medical charity Medicins Sans Frontiers (MSF) has opened the first care center in the current Ebola epidemic for pregnant women, whose survival rate from the virus is virtually zero, the charity said on Saturday....
An Ebola virus treatment center is seen in Bo, Sierra Leone, November 17, 2014. Credit: Reuters/Benjamin Black
There is currently one patient in the clinic, which is perched on a hill in the compound of a disused Methodist boys high school in the Sierra Leone capital.
Women are particularly vulnerable to a disease spread through direct contact with infected people and with the corpses of victims, because women often care for sick family members, said MSF Field Coordinator, Esperanza Santos.
Australian researchers reported on an automated text-message system used for actively monitoring people potentially exposed to Ebola. The system prompts contacts to submit information on symptoms and temperature twice a day. The Department of Health in Western Australia uses the system, called "EbolaTracks," to track travelers returning from West Africa and (potentially) contacts of any local cases.
Twenty-two people were enrolled in the program as of Jan 5, and 14 have completed active monitoring. The system sent 1,108 text messages and got a 91% response rate. Health officials followed up by phone when they didn't get a reply. Such systems could be valuable tools for larger-scale contact monitoring for Ebola or other infectious diseases, they concluded.
INTERNATIONAL BUSINESS TIMES by Jayalakshmi K Jan. 15, 2015
Researchers at DPZ, Germany, have developed a simple Ebola diagnostics kit that detects the virus in 15 minutes, without requiring any electricity, cold chain or lab equipment.
Infection researcher Dr Ahmed Abd El Wahed and the head of the Unit of Infection Models at the German Primate Center (DPZ), Dr med. vet. Christiane Stahl-Hennig, present the ebola suitcase laboratory Abd El Wahed invented.Karin Tilch, DPZ
The diagnostics-in-a-suitcase that comes equipped with all the required reagents is operated by an integrated solar panel and a power pack.
ASSOCIATED PRESS by Maria Cheng Jan. 9, 2015 LONDON --The World Health Organizationsays the two leading Ebola vaccines appear safe and will soon be tested in healthy volunteers in West Africa.
After an expert meeting this week, WHO said there is now enough information to conclude that the two most advanced Ebola vaccines ? one made by GlaxoSmithKline and the other licensed by Merck and NewLink ? have "an acceptable safety profile."
In a press briefing on Friday, Dr. Marie-Paule Kieny, who heads WHO's Ebola vaccine efforts, said "the cupboard (for Ebola vaccines) is filling up rapidly."
She said further trials in healthy people in West Africa, including health workers, are scheduled to start soon. Kieny added several other vaccines were being developed in the U.S., Russia and elsewhere.
The International Monetary Fund is preparing around $150 million in additional support to Liberia, Sierra Leone and Guinea, the countries at the heart of the Ebola epidemic, the Fund's representative in Liberia told Reuters on Thursday.
"In Guinea and Sierra Leone, existing Fund financial programs are being augmented to provide more resources to these countries. In Liberia, a one-off disbursement under the Fund's Rapid Credit Facility is being considered," Charles Amo-Yartey told Reuters in an email.
The money could be made available in the first quarter of this year and would add to $130 million disbursed by the Fund in September.
Infectious diseases are one of the many health issues that worry the organizers of mass gatherings, such as the Hajj and the World Cup. Geographers' tools of the trade can help event organizers to better plan, monitor and respond timely to such eventualities. The ways in which geographers gather, analyze, and visualize information provide health officials with clearer pictures of the transport routes and environmental factors that may further the spread of viruses to and from the attendees' home countries.
In Chapter 3 of the new book Health, Science and Place: A New Model, geographer and biologist Dr. Amy Blatt explains how geographic information is used for disease surveillance at mass gatherings. Read complete article
With the Ebola crisis far from over as a new year begins, both this current threat to global health as well as past infectious disease outbreaks carry important lessons for critical care providers, according to an article in the American Journal of Critical Care.
Because new pathogens are so unpredictable, "outbreaks reinforce the importance of critical care knowledge, skill and teamwork in uncertain situations," wrote Cindy L. Munro, R.N., Ph.D., and Richard H. Savel, M.D, both editors of the AJCC. "The recent Ebola outbreak reminds us that hand-washing, personal protective equipment and pristine technique are essential."
...Although a few smaller companies have become involved in the race for a vaccine, three major pharmaceutical makers are taking the lead—each pursuing a different vaccine. The trials are unprecedented for a variety of reasons, including the rapid timeline (trials of this nature generally take three to four years).
Steve Parsons-WPA Pool/Getty Images
Each individual race involves an unusual collaboration between researchers, manufacturers, and public-health entities. Together, the teams are working 24 hours a day for a product that promises much higher risk than it does profit.
Here’s what you need to know about the Ebola vaccine front-runners.
REUTERS by Ben Hirschler Jan. 6, 2015 LONDON --Johnson & Johnson has started clinical trials of its experimental Ebola vaccine, which uses a booster from Denmark's Bavarian Nordic, making it the third such shot to enter human testing.
The initiation of the Phase I study in Britain, which had been expected about now, marks further progress in the race to develop a vaccine against a disease that has killed more than 8,000 people in West Africa since last year.
Two other experimental vaccines, one from GlaxoSmithKline and a rival from NewLink and Merck, are already in clinical development. However, the J&J vaccine offers a different approach, since it involves two separate injections.
GENEVA --The clinical trial of an Ebola vaccine developed by Merck and NewLink resumed on Monday at a lower dose after a pause to assess complaints of joint pains in some volunteers, the University of Geneva hospital said.
The Geneva hospital announced on Dec. 11 that its vaccine trial had been suspended as a precautionary measure after four patients complained of joint pains. On Monday, the hospital said 10 of 59 volunteers who received the vaccine had felt pains in their joints "similar to rheumatism" after some two weeks, but these symptoms had disappeared rapidly without any treatment.
Swissmedic, the Swiss regulatory agency, and ethics and safety committees have approved the resumption of the trial at a lower dose, the hospital said in a statement.
Recent Comments